Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS.

Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000507. [Epub ahead of print]

PMID:
30216199
2.

Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population.

Wells PS, Prins MH, Beyer-Westendorf J, Lensing AW, Haskell L, Levitan B, Laliberté F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

Chest. 2018 Sep 7. pii: S0012-3692(18)32412-7. doi: 10.1016/j.chest.2018.08.1059. [Epub ahead of print]

3.

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.

Berger JS, Seheult R, Laliberté F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

Res Pract Thromb Haemost. 2017 Nov 15;2(1):58-68. doi: 10.1002/rth2.12050. eCollection 2018 Jan.

4.

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.

Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS.

Curr Med Res Opin. 2018 Aug 5:1-8. doi: 10.1080/03007995.2018.1501351. [Epub ahead of print]

PMID:
30009647
5.

An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution".

Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Lejeune D, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25165. [Epub ahead of print] No abstract available.

PMID:
29905381
6.

CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.

Laliberté F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S.

Curr Med Res Opin. 2018 Jun 12:1-8. doi: 10.1080/03007995.2018.1475347. [Epub ahead of print]

PMID:
29749269
7.

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.

McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P.

PLoS One. 2018 Apr 5;13(4):e0194099. doi: 10.1371/journal.pone.0194099. eCollection 2018.

8.

Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.

Berger JS, Peterson E, Laliberté F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR.

J Card Fail. 2018 Mar 27. pii: S1071-9164(18)30129-5. doi: 10.1016/j.cardfail.2018.03.012. [Epub ahead of print]

9.

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.

Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16.

PMID:
29469638
10.

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.

Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA.

Am J Hematol. 2018 May;93(5):664-671. doi: 10.1002/ajh.25059. Epub 2018 Feb 23.

11.

Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.

Weir MR, Haskell L, Berger JS, Ashton V, Laliberté F, Crivera C, Brown K, Lefebvre P, Schein J.

Clin Nephrol. 2018 May;89(5):314-329. doi: 10.5414/CN109281.

PMID:
29231162
12.

Pseudogap phase of cuprate superconductors confined by Fermi surface topology.

Doiron-Leyraud N, Cyr-Choinière O, Badoux S, Ataei A, Collignon C, Gourgout A, Dufour-Beauséjour S, Tafti FF, Laliberté F, Boulanger ME, Matusiak M, Graf D, Kim M, Zhou JS, Momono N, Kurosawa T, Takagi H, Taillefer L.

Nat Commun. 2017 Dec 11;8(1):2044. doi: 10.1038/s41467-017-02122-x.

13.

Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.

Kaatz S, Coleman CI, Bookhart B, Laliberté F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P.

Curr Med Res Opin. 2018 Feb;34(2):275-284. doi: 10.1080/03007995.2017.1409200. Epub 2017 Dec 22.

PMID:
29164990
14.

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C, Schein JR, Lefebvre P, Peterson ED.

J Manag Care Spec Pharm. 2017 Sep;23(9):980-988. doi: 10.18553/jmcp.2017.23.9.980.

15.

Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.

Faught E, Laliberté F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS.

Epilepsia. 2017 Oct;58(10):1742-1748. doi: 10.1111/epi.13857. Epub 2017 Jul 25.

PMID:
28741690
16.

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.

Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 21;12:1825-1836. doi: 10.2147/COPD.S129007. eCollection 2017.

17.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S.

Clin Ther. 2017 Jul;39(7):1396-1408. doi: 10.1016/j.clinthera.2017.05.357. Epub 2017 Jun 20.

PMID:
28645879
18.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J.

Curr Med Res Opin. 2017 Oct;33(10):1891-1900. doi: 10.1080/03007995.2017.1339674. Epub 2017 Jul 11.

PMID:
28590785
19.

Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.

Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Yannicelli D, Schein J.

Res Pract Thromb Haemost. 2017 May 30;1(1):14-22. doi: 10.1002/rth2.12002. eCollection 2017 Jul.

20.

Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.

Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, Lefebvre P, Peterson ED.

Curr Med Res Opin. 2017 Jun;33(6):1033-1043. doi: 10.1080/03007995.2017.1297932. Epub 2017 Apr 2.

PMID:
28366075
21.

Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.

Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Curr Med Res Opin. 2017 Apr;33(4):631-638. doi: 10.1080/03007995.2016.1275936. Epub 2017 Jan 24.

PMID:
28008771
22.

Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.

McHorney CA, Peterson ED, Laliberté F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

Clin Ther. 2016 Nov;38(11):2477-2488. doi: 10.1016/j.clinthera.2016.09.014. Epub 2016 Oct 24.

PMID:
27789043
23.

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

Law A, Pilon D, Lynen R, Laliberté F, Gozalo L, Lefebvre P, Duh MS.

Reprod Health. 2016 Aug 22;13(1):96. doi: 10.1186/s12978-016-0211-3.

24.

Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.

Deitelzweig S, Laliberté F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Clin Ther. 2016 Aug;38(8):1803-1816.e3. doi: 10.1016/j.clinthera.2016.07.002. Epub 2016 Aug 2.

PMID:
27491278
25.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.

Simon JA, Laliberté F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Menopause. 2016 Jun;23(6):600-10. doi: 10.1097/GME.0000000000000590.

PMID:
26953655
26.

Change of carrier density at the pseudogap critical point of a cuprate superconductor.

Badoux S, Tabis W, Laliberté F, Grissonnanche G, Vignolle B, Vignolles D, Béard J, Bonn DA, Hardy WN, Liang R, Doiron-Leyraud N, Taillefer L, Proust C.

Nature. 2016 Mar 10;531(7593):210-4. doi: 10.1038/nature16983. Epub 2016 Feb 22.

PMID:
26901870
27.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.

LaMori J, Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

J Med Econ. 2016;19(4):364-73. doi: 10.3111/13696998.2015.1127252. Epub 2016 Jan 11.

PMID:
26624985
28.

Computerized tomography based tumor-thickness measurement is useful to predict postoperative pathological tumor thickness in oral tongue squamous cell carcinoma.

Madana J, Laliberté F, Morand GB, Yolmo D, Black MJ, Mlynarek AM, Hier MP.

J Otolaryngol Head Neck Surg. 2015 Nov 16;44:49. doi: 10.1186/s40463-015-0089-z.

29.

Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma.

Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleó L, Yolmo D, Black MJ, Sultanem K, Hier MP.

Head Neck. 2016 Apr;38 Suppl 1:E1277-80. doi: 10.1002/hed.24210. Epub 2015 Oct 30.

PMID:
26514270
30.

Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.

Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberté F, Dea K, Germain G, Lynch SM.

J Med Econ. 2015;18(12):1074-84. doi: 10.3111/13696998.2015.1076429. Epub 2015 Sep 25.

PMID:
26407193
31.

Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.

McHorney CA, Crivera C, Laliberté F, Nelson WW, Germain G, Bookhart B, Martin S, Schein J, Lefebvre P, Deitelzweig S.

Curr Med Res Opin. 2015 Dec;31(12):2167-73. doi: 10.1185/03007995.2015.1096242. Epub 2015 Oct 22.

PMID:
26393483
32.

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.

Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart B, Pollack CV.

J Med Econ. 2016;19(1):84-90. doi: 10.3111/13696998.2015.1096274. Epub 2015 Oct 27.

PMID:
26390315
33.

Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.

Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberté F, Schein J, Lefebvre P.

Curr Med Res Opin. 2015;31(10):1889-95. doi: 10.1185/03007995.2015.1077213. Epub 2015 Sep 4.

PMID:
26211815
34.

Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.

Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

J Med Econ. 2015;18(12):1041-9. doi: 10.3111/13696998.2015.1074583. Epub 2015 Aug 26.

PMID:
26201251
35.

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Apr;32(4):387. doi: 10.1007/s12325-015-0202-8. No abstract available.

36.

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.

Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Olson WH, Pollack CV Jr.

Hosp Pract (1995). 2015;43(2):85-93. doi: 10.1080/21548331.2015.1021659. Epub 2015 Mar 19.

PMID:
25791984
37.

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Mar;32(3):216-27. doi: 10.1007/s12325-015-0189-1. Epub 2015 Mar 18. Erratum in: Adv Ther. 2015 Apr;32(4):387.

38.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Clin Ther. 2015 Mar 1;37(3):554-62. doi: 10.1016/j.clinthera.2015.02.001. Epub 2015 Mar 4. Erratum in: Clin Ther. 2015 Aug;37(8):1870-1.

39.

Reply: Essential need for research in hepatitis C.

Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

J Med Econ. 2015;18(7):514-5. doi: 10.3111/13696998.2015.1017504. Epub 2015 Apr 24. No abstract available.

PMID:
25744591
40.

Review of the fundamental theories behind small angle X-ray scattering, molecular dynamics simulations, and relevant integrated application.

Boldon L, Laliberte F, Liu L.

Nano Rev. 2015 Feb 25;6:25661. doi: 10.3402/nano.v6.25661. eCollection 2015.

41.

Atmospheric dynamics. Constrained work output of the moist atmospheric heat engine in a warming climate.

Laliberté F, Zika J, Mudryk L, Kushner PJ, Kjellsson J, Döös K.

Science. 2015 Jan 30;347(6221):540-3. doi: 10.1126/science.1257103.

42.

Evidence for a small hole pocket in the Fermi surface of underdoped YBa2Cu3Oy.

Doiron-Leyraud N, Badoux S, René de Cotret S, Lepault S, LeBoeuf D, Laliberté F, Hassinger E, Ramshaw BJ, Bonn DA, Hardy WN, Liang R, Park JH, Vignolles D, Vignolle B, Taillefer L, Proust C.

Nat Commun. 2015 Jan 23;6:6034. doi: 10.1038/ncomms7034.

43.

Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.

Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Thromb Res. 2015 Feb;135(2):303-10. doi: 10.1016/j.thromres.2014.11.024. Epub 2014 Dec 4.

44.

Gastrointestinal comorbidities associated with atrial fibrillation.

Laliberté F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

Springerplus. 2014 Oct 15;3:603. doi: 10.1186/2193-1801-3-603. eCollection 2014.

45.

Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.

Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Hosp Pract (1995). 2014 Aug;42(3):17-25. doi: 10.3810/hp.2014.08.1114.

PMID:
25255403
46.

Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.

Olson WH, Ma YW, Laliberté F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

J Clin Pharm Ther. 2014 Dec;39(6):663-72. doi: 10.1111/jcpt.12209. Epub 2014 Sep 23.

PMID:
25252190
47.

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.

Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

J Med Econ. 2014 Dec;17(12):862-71. doi: 10.3111/13696998.2014.964720. Epub 2014 Oct 8.

PMID:
25215925
48.

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?

Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Aug;30(8):1521-8. doi: 10.1185/03007995.2014.916159. Epub 2014 May 2.

PMID:
24758611
49.

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.

Laliberté F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.

Curr Med Res Opin. 2014 Aug;30(8):1513-20. doi: 10.1185/03007995.2014.915801. Epub 2014 May 2.

PMID:
24738644
50.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Jul;30(7):1317-25. doi: 10.1185/03007995.2014.907140. Epub 2014 Apr 2.

PMID:
24650301

Supplemental Content

Loading ...
Support Center